Status:
RECRUITING
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Peking University
Guangdong Provincial People's Hospital
Conditions:
Non-small Cell Lung Cancer
Minimal Residual Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small...
Detailed Description
Approximately 30% of early-stage lung cancer patients experience recurrence after curative surgery. However, the clinical utility of routine chest CT surveillance remains limited. Emerging evidence ha...
Eligibility Criteria
Inclusion
- Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy
- Solid nodules \>1 cm or ground-glass nodules \>1.5 cm on imaging
- No history of malignancies other than non-small cell lung cancer in the past 5 years
- Specimens are well preserved and imaging documents are accessible.
Exclusion
- Age\<18 years old
- Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification)
- Pathology results confirmed not to be non-small cell lung cancer
- History of malignancies other than non-small cell lung cancer in the past 5 years
Key Trial Info
Start Date :
March 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2028
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06930807
Start Date
March 25 2025
End Date
July 31 2028
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044